AI주식인사이트AI Stock Insight
C

신테카바이오

226330KOSDAQ

49.0 / 100

Reference Date: 2026-10-23

Financial Score21.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 14.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Synetica Bio is a biotech venture company established in 2009, specializing in AI-driven drug discovery platforms and genomics big data solutions. Its core services include DeepMatcher® hit screening, personalized neoantigen identification (NEO-ARS®), and genomic precision medicine (NGS-ARS®), with revenue generated through both platform services and in-house drug pipelines. The company leverages its supercomputing infrastructure and partnerships to maintain a competitive edge in the industry.

Number of Employees

49people

Average Salary

61.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.77Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-61.27Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
7.90Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲1367.3% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -41.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,013Won52-week high 5,90052-week low 1,009
1-month return1.0Point

1m -14.87% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 1Neutral 8Negative 0
  • Neutral주식매수선택권부여에관한신고2026-10-16
  • Neutral임시주주총회결과2026-10-16
  • Neutral주주명부폐쇄기간또는기준일설정2026-10-14
  • Neutral주주총회소집결의 (임시주주총회)2026-10-14
  • Neutral주식등의대량보유상황보고서(약식)2026-10-12